CytoGenix, Inc. Announces the Appointment of a New Chairman of the Board of Directors

CytoGenix, Inc. Announces the Appointment of a New Chairman of the Board of Directors


NEW BRAUNFELS, Texas--(BUSINESS WIRE)--Sep 13, 2010 - CytoGenix, Inc. (Pink sheets: CYGX) today announced that Cy Stein, MD, PhD has been appointed as Chairman of the CYGX Board of Directors replacing Randy Moseley. Dr. Stein has been on the CytoGenix Board for 7 years and has served as Chairman of the CytoGenix Scientific Advisory Board.

Dr. Stein is a Professor of Medicine and Molecular Pharmacology at the Albert Einstein College of Medicine (Bronx, NY), and the Director of Medical Genitourinary Oncology and Attending Physician at the Montefiore Medical Center. For the past 22 years, he has been heavily involved in preclinical and clinical studies of nucleic acid therapies for cancers. He has previously served as Head of Scientific Advisory Board at Novosom AG (Halle, DL), and as a member of the Scientific Advisory Boards of Celadon Labs (Baltimore, MD), ProNai Therapeutics (Kalamazoo, MI), Silence Therapeutics (Berlin, DL), Genta (Berkeley Heights, NJ), Gentium (Como, IT) and TriLink Biotechnologies (La Jolla, CA). He has also been a Member of Scientific Advisory Board of Benitec Ltd. (Melbourne, AU), since June 2007, and of Nanoviricides Inc. (West Haven, CT), since July, 2005. He has also served as a Director of Salus Therapeutics, Inc. (Salt Lake City, UT) before its acquisition and as a consultant to Altana Pharma (Konstanz, DL) and Pfizer (Cambridge, MA). More recently, he has been consulting CMO for Tokai Pharmaceuticals (Cambridge, MA).

In addition to his clinical and faculty activities, he serves as Co-editor-in-Chief of the journal Oligonucleotides (formerly Antisense and Nucleic Acid Drug Development), and is an ad hoc Reviewer for over 20 peer reviewed journals. He has authored or co-authored over 115 scientific publications, over 75 editorials, book chapters and reviews, as well as being a named inventor on eleven issued patents. He serves on seven editorial advisory boards, including Molecular Cancer Therapeutics and Clinical Cancer Research.

Before attaining his current position, he was a faculty member at the College of Physicians and Surgeons at Columbia University for 13 years, first as an Assistant Professor of Medicine and then as an Associate Professor of Pharmacology and Medicine. Dr. Stein is also a practicing genitourinary oncologist who has been cited many times as one of the "Best Doctors in NY" by New York Magazine. He is a Diplomate of nearly 25 years' standing of both the American Board of Internal Medicine and the American Board of Oncology. Dr. Stein was a Clinical Associate and Senior Staff Fellow at The National Cancer Institute, Bethesda, Maryland. He was trained at the New York Hospital/Cornell Medical Center and the National Institutes of Health. He completed an Internship and Residency in Internal Medicine at New York Hospital - Cornell Medical Center. He received a Bachelor of Arts from Brown University in 1974, a Ph.D. in Organic Chemistry in 1978 from Stanford University and Medical Degree from Albert Einstein College of Medicine in 1982.

Lex Cowsert, CEO of CYGX stated, "Dr. Stein has repeatedly demonstrated by his tenacious commitment to CYGX his desire to see the bio-technology discoveries of CYGX become commercialized for the betterment of society. Dr. Stein as the new Chairman of the Board of Directors brings his strong vision and unwavering work ethics to the board as a model which we can all follow. Dr. Stein has displayed uncompromising integrity and leadership while a Director and Chairman of the Board of Advisors which will undoubtedly carry over to his new role as Chairman of the Board of Directors. We are excited to finally having a significant, strong Board of Directors with confidence and vision which will further enable our company the ability to see significant revenue within the coming months. Having a Chairman of the Board with the ability to take a decisive direction will make all our jobs easier; we are lucky to have him. There are many positive new changes which we will be announcing in the coming weeks at CYGX, and a New Chairman of the Board and a New CFO is only the beginning".

Dr. Cy Stein, Chairman of the Board of Directors of CYGX stated. "I am honored and excited about this new role at CytoGenix. It is clear that this company and its shareholders have demonstrated through the years their ultimate desire to have the technologies of CytoGenix on the market for global use. I personally believe in the new break-though biotechnology product line at CytoGenix and look forward to seeing these and other new development technologies placed into the market. Building a strong product line will enhance shareholder value and build a strong viable company for its future. I am looking forward to working with the new team of key people within CytoGenix organization. They have built and demonstrated a vision and plan that we are finally able to implement, which will hopefully bring unprecedented revenue to CytoGenix in the coming years."

CytoGenix, Inc.

CytoGenix is a Nevada corporation traded under the symbol: CYGX.PK. CytoGenix is a biotechnology company developing biotechnology derived products for vaccines and therapeutic applications for human, agricultural and veterinary markets. As such, CytoGenix has access to a broad range of biological expertise that can be leveraged to identify, evaluate, develop and commercialize biologically based technologies for energy production.

Safe Harbor Statement

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Important factors, including general economic conditions, spending levels and other factors could cause actual results to differ materially from the Company's expectations.

 

Contact: CytoGenix, Inc.
Lex M. Cowsert, 830-632-5944
[email protected]

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.